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ABSTRACT
Overexpression of HER2 is an important prognostic marker, and the only 
predictive biomarker of response to HER2-targeted therapies in invasive breast cancer. 
HER2-HER3 dimer has been shown to drive proliferation and tumor progression, and 
targeting of this dimer with pertuzumab alongside chemotherapy and trastuzumab, 
has shown significant clinical utility. The purpose of this study was to accurately 
quantify HER2-HER3 dimerisation in formalin fixed paraffin embedded (FFPE) breast 
cancer tissue as a novel prognostic biomarker.
FFPE tissues were obtained from patients included in the METABRIC (Molecular 
Taxonomy of Breast Cancer International Consortium) study. HER2-HER3 dimerisation 
was quantified using an improved fluorescence lifetime imaging microscopy (FLIM) 
histology-based analysis. Analysis of 131 tissue microarray cores demonstrated that 
the extent of HER2-HER3 dimer formation as measured by Förster Resonance Energy 
Transfer (FRET) determined through FLIM predicts the likelihood of metastatic relapse 
up to 10 years after surgery (hazard ratio 3.91 (1.61–9.5), p = 0.003) independently 
of HER2 expression, in a multivariate model. Interestingly there was no correlation 
between the level of HER2 protein expressed and HER2-HER3 heterodimer formation. 
We used a mathematical model that takes into account the complex interactions in a 
network of all four HER proteins to explain this counterintuitive finding. 
Future utility of this technique may highlight a group of patients who do not 
overexpress HER2 protein but are nevertheless dependent on the HER2-HER3 
heterodimer as driver of proliferation. This assay could, if validated in a group of 
patients treated with, for instance pertuzumab, be used as a predictive biomarker to 
predict for response to such targeted therapies.
               Research Paper
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INTRODUCTION
The human epidermal growth factor receptors HER2 
(ErbB2) and HER3 (ErbB3) are members of the HER 
family of receptor tyrosine kinases [1]. They are important 
in the development of cancer and the over-expression 
of HER2 has been shown to increase the downstream 
signalling of ERK1/2 and PI3K/Akt leading to tumor 
promotion [2]. 
The HER2-HER3 dimer is central to oncogenic 
proliferation and the HER2 receptor has been used to 
identify a subgroup of breast cancer patients with poor 
prognosis, but is specifically also a target for therapy. HER2 
overexpression or gene amplification is the only validated 
predictive biomarkers in use for the stratification of breast 
cancer patients for targeted therapies such as trastuzumab 
(HER2-targeted), pertuzumab (a monoclonal antibody 
targeted against HER2-HER3 dimerisation with other 
HER receptors), TDM-1 and lapatinib (against both EGFR 
(HER1) and HER2) [3–5]. Over the last 2 decades, although 
a variety of HER2-targeted therapies have been developed 
[6], novel predictive tools for patient selection have failed 
to be validated. For instance, despite extensive biomarker 
analyses of samples from the CLEOPATRA study, 
including serum markers, ligands to HER family members, 
expression levels of HER family members by mRNA and 
immunohistochemistry (IHC), and intracellular pathway 
markers, HER2 protein overexpression determined by IHC 
or HER2 amplification by fluorescent in situ hybridisation 
(FISH) remained the only predictive marker for patient 
selection for the trastuzumab and pertuzumab combination 
[7]. In this clinical trial high levels of HER2 and HER3 
mRNA were prognostic of improved progression free 
survival with modest hazard ratios (HR) of 0.77 and 0.81 
respectively. The HR for HER2 membranous expression 
by IHC was not found to be significant (HR of 0.83 and a 
p-value of 0.05).
These results reinforce the need for more accurate 
patient stratification beyond the Food and Drug 
Administration-approved assays that measure HER2 
protein expression such as the HercepTest [3, 8], that are 
used to identify HER2 positive tumors as appropriate for 
HER2 targeted treatment. The use of additional anti-HER2 
dimerization targeted agents in the neoadjuvant setting has 
demonstrated improved complete pathological response 
rates (pCR), which led to the postulation that de-escalation 
of treatment may be a viable option for some patients [9]. 
For instance, without patient stratification, a combination 
of the targeted drugs, trastuzumab and pertuzumab, 
produced a pCR of 16.8% (compared to 45.8% pCR for 
patients on the targeted drugs plus docetaxel). Similarly 
patients with metastatic HER2-positive breast cancer may 
receive combination chemotherapy with trastuzumab 
and pertuzumab (CLEOPATRA [10, 11]), but there is 
no evidence for the use of the targeted drugs alone. 
However, some patients may potentially be able to avoid 
chemotherapy entirely, whilst patient stratification with 
HER2 related biomarkers should also lead to increased 
response rates in those receiving targeted agents plus 
chemotherapy. In the modern era, the challenge for HER2 
positive breast cancer is not only to continue to improve 
efficacy, but to decrease toxicity and cost, potentially with 
the development of better biomarkers
Although there have been major advances in our 
understanding of the cancer genome on the basis of large 
scale sequencing efforts such as The Cancer Genomic 
Atlas (TCGA), International Cancer Genome Consortium 
(ICGC) and METABRIC, the functional consequences 
of many recently revealed genomic alterations, including 
somatic mutations, remain unclear. For HER2, somatic 
mutations are rarely found but the HER2(YVMA) 
insertion mutant has been shown to have a higher 
autocatalytic activity than that of its WT equivalent 
in vitro [12]. Mutations that sensitize tumors to targeted 
therapies, such as that found in EGFR [13], have so far 
not been identified for HER2 in the breast cancer setting.
We have, in recent years, used an imaging 
approach to investigate individual patients’ intact tissues 
at a subcellular and nanometer proximity level, so as to 
obtain a deeper understanding of the protein complexes 
and sub-networks, including the HER family, within 
tumor cells, in order to achieve an improved monitoring 
of treatment responses and to derive biomarkers that 
can be used in a patient-specific manner [14–19]. As an 
example, we recently described the first clinical utilization 
of a fluorescence lifetime imaging microscopy (FLIM) 
histology assay to quantify the level of HER1-HER3 
dimer formation in formalin-fixed paraffin-embedded 
(FFPE) basal-like breast cancer tissues from patients 
treated unsuccessfully with anti-EGFR treatments 
(cetuximab or panitumumab). Post-treatment biopsies 
were obtained from patients with residual cancer and 
compared to pre-treatment samples. An increase in the 
amount of HER1-HER3 dimer (as part of the HER protein 
network rewiring) was shown to be a mechanism of anti-
EGFR treatment resistance in this neoadjuvant study 
[14]. We hypothesize that this approach may also be of 
utility in stratifying patients for HER2 treatment, given 
the absence of obvious mutations that can report on HER2 
sensitivity to targeted therapies, as well as the suboptimal 
and relatively heterogeneous response rate to molecular 
therapeutics [20].
As HER3 has been shown to be the preferred 
interaction partner of HER2 [21, 22] and as pertuzumab 
is targeted against this interaction, several groups have 
attempted to quantify HER2-HER3 dimerisation in 
different cell types and xenograft models [23] as well 
as in FFPE samples [23, 24]. These studies use either 
the Proximity Ligation Assay (PLA) or the VeraTag 
assay, which can both detect proteins in close proximity, 
inferring interaction. However, for the PLA assay, the 
maximum distance between antigenic determinants 
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recognized by two antibodies that are directly conjugated 
to oligonucleotides, has been estimated to be roughly 
30 nm, including the size of the two antibodies and the 
connecting oligonucleotides [25]. The equivalent distance 
can be up to 300 nm for the VeraTag assay [26, 27]. Using 
the PLA technique (primary plus secondary antibodies 
conjugated to oligonucleotides), high levels of HER2-
HER2 and HER2-HER3 protein proximity have previously 
been shown to be correlated with HER2 amplification/
overexpression, using 88 and 74 cases of human breast 
carcinomas for HER2-HER2 and HER2-HER3 PLAs, 
respectively [24]. 
We used a combination of fluorescence lifetime 
imaging microscopy and Förster Resonance Energy 
Transfer (FLIM-FRET) [16, 18, 28, 29], which has become 
the accepted gold standard technique for measuring protein 
proximity, typically within the < 10 nm range (between the 
centres of the donor and acceptor fluorophores, that label 
the antibodies), to quantify in situ interactions between 
HER2 and HER3 in FFPE tissue. Part of the difficulty 
of accurately determining the fluorescence lifetime of 
fluorophores in FFPE tissue is the presence of interfering 
endogenous and preparation-induced fluorescence emission 
in both stromal and epithelial components [30, 31]. These 
same contaminating “autofluorescence” components also 
interfere with non-FLIM applications such as confocal laser 
scanning microscopy (CLSM) although this is often not 
obvious when intensity is the measured ‘signal’. In order 
to accurately quantify dimers, we employed our recently 
improved FLIM histology technique and its associated 
analysis algorithm [32] derived specifically to circumvent 
the problem of contaminating fluorescence signals in FFPE 
tissues. We showed that HER2-HER3 dimer quantification 
by FLIM-FRET does not correlate with HER2 protein 
expression by IHC, contrary to the previously reported 
finding [24]. This was further supported by the lack of 
correlation between HER2 and HER3 mRNA levels and 
HER2-HER3 dimer quantification by FLIM-FRET. This 
novel biomarker predicts breast cancer metastatic relapse 
independently of HER2 expression, up to 10 years post-
surgery, in a multivariate model.
RESULTS
Validation of the HER2-HER3 dimer assay
The scoring of HER2 protein immunohistochemical 
expression patterns in breast cancer patients is a well-
established protocol with commercially available 
validated antibodies (e.g. HercepTest, DAKO), Similar 
staining intensities and patterns of HER2 localization 
in tumor cells were obtained using the directly labelled 
anti-HER2 IgG, compared to those obtained using the 
conventional IHC method (Supplementary Figure S1A). 
Alexa546-conjugated anti-HER3-IgG was validated in 
FFPE cells overexpressing HER3 protein (Supplementary 
Figure S1B). HER3 expression in tumor samples was 
assessed and categorised into two groups with either 
predominantly membrane or cytoplasmic staining, and 
into a range of different expression levels was seen 
(Supplementary Figure S1C). Both the pattern and intensity 
of staining were recorded by a histopathologist (Table 1).
Fluorophore-labelled antibodies for the FLIM-FRET 
assay (Figure 1A) were tested in FFPE SKBR3 cell pellets, 
mimicking the conditions of tumor tissue fixation and 
processing. In control cells a low level of interaction was 
detected between HER2 and HER3 (Figure1B, small shift 
to the red end of the spectrum on the pseudo-colour image 
with the acceptor, Cy5, resulting in a lifetime reduction of 
Alexa546 (X546) due to FRET between the two proteins in 
close proximity). Conversely, in cells treated with the HER3 
ligand NRG-1 (which causes HER dimer formation [33]), 
a statistically significant increase in interaction between 
HER2 and HER3 proteins was obtained (Figure 1C, 2% vs. 
6%, P = 0.004, marked shift to the red in lifetime image, 
Figure 1B). Thus the ability of the chosen antibodies 
to specifically recognize the target proteins and report 
interaction between them in FFPE samples was confirmed. 
Validation of this HER2-HER3 FLIM-based dimer assay 
is being performed in other cell lines (such as colorectal), 
using a range of stimuli (EGF, NRG1, etc) as well as 
commonly used  anti-EGFR therapeutics (both tyrosine 
kinase inhibitor and anti-EGFR antibody). Some specificity 
with respect to ligand requirement (no enhancement with 
EGF for instance) has been observed (data not presented) in 
addition to inhibitor-induced HER2-HER3 dimer formation 
(which is analogous to our previously reported drug-
induced EGFR homodimer [34, 35]).
Measurements of HER2-HER3 dimer levels in 
human tumors
A total of 152 cores were present on the TMA 
sections used for FLIM imaging, FLIM images from 131 
cores were suitable for use for further analysis and survival 
modelling. Table 1 demonstrates the tumor characteristics 
within the FRET ‘high’ and ‘low’ groups (classified using 
ROC analysis, see materials and methods). There were no 
significant differences between the 2 groups, but there was 
a trend to significance for an association with lymph node 
status: patients with low FRET tumors were more likely 
to have node positive disease, with the majority having 
1–3 nodes involved, compared to those with high FRET 
tumors, who were more likely to have tumor-free lymph 
nodes.
The measured FRET efficiency ranged from 0% to 
22% across the 131 tumor samples (Figure 2A–2B) with 
an average value of 7.7 ± 0.4% (mean ± SEM, Figure 2C). 
Since the expression level of HER2 is an established 
criterion to predict prognosis and drug response of breast 
cancer [36, 37], the interaction between FRET efficiency 
(reflecting HER2-HER3 dimer formation) and protein 
Oncotarget51015www.impactjournals.com/oncotarget
Table 1: Clinico-pathological characteristics of patients in METABRIC cohort in king’s health 
partners cancer biobank
Number (%) of 
patients N = 131 (100%)
Number of 
patients
FRET efficiency High (> 8.56%) 53 (40%) FRET efficiency High   Low
Fisher's
exact test P
Low (< 8.56%) 78 (60%) 25 40
HER3 localisation C 65 (50%) 13 21
C + M 34 (26%) 13 14 0.67
M/M + C 27 (21%)
Not available 5 (4%) 5 17
HER2 status (TMA IHC) Positive 22 (17%) 38 56 0.15
Negative 94 (72%)
Not available 15 (11%) 47 63
ER status Positive 110 (84%) 6 15 0.33
Negative 21 (16%) 27 50
PR status Positive 77 (59%) 26 28 0.15
Negative 54 (41%) 17 36
Clinical tumour size < 20 mm 53 (40%) 36 42 0.15
> 20 mm 78 (60%) 3 12
Histological grade 1 15 [11%) 17 28
2 45 (34%) 30 35 0.18
3 65 (50%)
Not available 6 (5%) 26 25
Lymph nodes positive 0 51 (39%) 17 41
1–3 58 (44%) 9 12 0.06
4+ 21 (16%)
Not available 1 (1%) 7 17
Age < 50 yr 24 (18%) 46 61 0.25
> 50 yr 107 (82%)
Menopausal status Pre 23 (18%)
Post 103 (79%)
Peri 4 (3%)
Not available 1 (1%) 42 60
Treatment (endocrine) Yes 102 (78%) 11 18 0.83
[Al/Endo/Endocrine/TAM/
TAM;AI] No 29 (22%) 10 20
Treatment (chemotherapy) Yes 30 (23%) 43 58 0.40
[APD/Chemo/CMF/Taxoid] No 101 (77%)
Time to distant metastasis Number of events = 37
Median (event) = 2.7 yr
Median (event or last 
follow-up) = 7.6 yr
[Al / Endo / Endocrine / TAM / TAM;AI] [APD / Chemo / CMF / Taxoid]
[None / (no entry)] [None / (no entry)]
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expression of HER2 using standard IHC scoring system 
was tested.
Surprisingly, in contrast to previously published data 
with PLA, IHC and FISH techniques [24],  no correlation 
between FRET efficiency and HER2 scoring values 
derived from traditional IHC staining using HercepTest 
was observed (Figure 2C). 
In order to corroborate these findings, mRNA levels 
of HER2 and HER3 were assessed. Figure 3 demonstrates 
that mRNA levels of HER2 and HER3 were positively 
correlated amongst HER2 negative tumors, consistent with 
findings published from the MAPLE study [38]. However, 
samples with high FRET efficiency (red circles) were not 
restricted to samples with high HER2 and HER3 mRNA 
levels, consistent with our finding that HER2 protein 
levels were not correlated with HER2-HER3 dimerization 
as measured by FRET efficiency. These results are novel 
and suggest that neither HER2 and HER3 mRNA levels 
nor HER2 protein expression are accurate surrogates for 
estimating HER2-HER3 dimerization as measured by 
FLIM-FRET, which is based on a fundamentally stringent 
requirement of a < 10 nm proximity between the centres 
of the donor and acceptor fluorophores, that label the 
antibodies (Figure 1A), and provides highly specific 
detection of interaction.
Mathematical models of EGFR family member 
interactions
The independence of HER2-HER3 interaction on their 
relative concentrations in the samples was a counterintuitive 
finding when taking into account previously published work 
(both experimental (HER2-HER3) and theoretical (HER2-
EGFR) literature [24, 39, 40]). Although dependence of 
Figure 1: Detection of HER2-HER3 interaction in FFPE cells samples by FRET-FLIM assay. (A) Schema illustrating 
the principle of antibody-based FRET-FLIM assay. Energy transfer (FRET) occur between donor fluorophore (Alexa546) and acceptor 
fluorophore (Cy5) upon excitation of donor only at distance less than 10 nm between fluorophores. (B) Interaction between HER2 and HER3 
proteins induced by NRG1 treatment. Detected with anti-HER3-IgG-Alexa546 (donor) and anti-HER2-IgG-Cy5 (acceptor) antibodies in 
FFPE SKBR3 cells. Pseudocolour map shows distribution of measured lifetime where red/yellow pixels represents low lifetime - higher 
level of HER2-HER3 dimer). Scale bar = 60 µm. (C) Quantification of the result presented in A.
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HER2-HER3 dimer on HER2 and HER3 may be expected 
if HER2-HER3 binding is an isolated event (e.g. in vitro 
condition), it is clear that in vivo HER2 and HER3 are part 
of a wider network of interacting EGFR family receptors 
consisting of at least four members (HER1-4) that are 
known to undergo multiple homo- and hetero-dimerization 
interactions in addition to HER2-HER3 binding. We 
therefore hypothesized that this complexity may result in a 
lack of correlation between HER2-HER3 dimerization and 
the total abundances of HER2 and HER3. In order to test 
this hypothesis, dynamic mathematical models of the EGFR 
family receptors interaction network were constructed and 
used to simulate and analyse the correlation of the HER2-
HER3 dimer level with the total abundance of HER2 and 
HER3 proteins. 
The first model, for simplicity, considered only 
HER2-HER3 dimerization and binding to a third receptor, 
in this case HER1 (Figure 4A). Simulations were run 
for 400 hypothetical patients where abundances of the 
receptors for each patient were randomly drawn from 
normal distributions. These commonly demonstrated a 
lack of correlation between HER2, HER3 and the HER2-
HER3 dimer (Figure 4C, 4D). (Detailed descriptions of the 
model and simulation implementation are provided in the 
Supplementary Material).
Next the abundance of HER1 within these 
simulations was manipulated to examine its effect upon 
the correlation (Figure 4C). The higher the relative level 
of HER1 compared to HER2 and HER3, the poorer the 
correlation between HER2-HER3 dimerization and 
expression of HER2 or HER3. In addition, such lack of 
correlation is also observed if either HER2 or HER3 is 
significantly less expressed than the other (Figure 4D).
Conversely, if HER2 is over-expressed, becoming 
much more abundant than HER1 or HER3, good 
correlation between HER2-HER3 and HER3 was observed 
compared to a significant lack of correlation between 
HER2-HER3 and HER2 (Supplementary Figure S2B). 
The opposite scenario is true if HER3 becomes the over-
expressed receptor (Supplementary Figure S2C). Thus, the 
presence of a significantly more abundant binding partner 
of HER2 and HER3 destroys any correlation between that 
receptor and its dimer(s). 
The hypothesis was further tested by considering 
a more detailed model that consisted of all four EGFR 
family members (Figure 4B). The dimerization events 
in this model have been experimentally reported and 
included in previously published models [41]. Importantly, 
a significant lack of correlation between the levels 
of HER2, and HER3 and their dimer was commonly 
Figure 2: Relationship between HER2-HER3 dimer and expression of proteins in patients’ samples. (A) Representative 
images of tumors with low (upper panels) and high (bottom panels) levels of HER2-3 interaction. (B) Distribution of FRET efficiency 
signal across patients’ tumor cores on Guy’s METABRIC TMAs (N = 131). (C) FRET efficiency (mean ± SEM) shown by available HER2 
IHC scores (0,1,2,3; HercepTest) and for all imaged cores.
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observed if similar conditions as in the reduced model in 
Figure 4A, were applied, i.e. if HER2 and HER3 are less 
abundant than HER1 (Figure 4E). The poor correlation 
is further amplified when HER4 is also over-expressed. 
Taken together, our model simulations and the analysis 
have confirmed our hypothesis and furthermore have 
teased out potential scenarios where the lack of HER2 
and HER3 correlation with their dimer is common. 
In reality, as HER2 and HER3 also bind many other 
proteins outside of the EGFR family [42], it is even more 
likely to observe weak to no correlation between HER 
member overexpression and their associated dimers from 
experimental data.
HER2-HER3 dimerization is associated with 
metastatic relapse in breast cancer patients
Within the whole TMA cohort (n = 218), in 
univariate Cox survival models, HER2 status was 
significantly associated with metastasis-free survival at 
5 years (Figure 5A). Within the cohort for which FLIM 
was feasible (n = 131) tumor samples were assigned as 
‘high’ or ‘low’ FRET efficiency as a quantification of 
HER2-HER3 dimer formation. The FRET efficiency 
threshold (FRET efficiency = 8.56%) was selected using 
an exploratory ROC curve analysis to identify an optimal 
dichotomization (see Methods). 
High FRET efficiency was associated with poor 
metastasis-free survival during a10-year follow-up period 
(Figure 5B). This observation was not explained by the 
HER2 status of the tumor samples by IHC (p = 0.67 by 
Fisher’s exact test correlating HER2 IHC and FRET 
efficiency, Table 1). In univariate Cox survival models, 
additionally to high/low FRET efficiency (HR = 2.03, 
CI = 1.32–6.29), ER status and lymph node burden were 
significantly associated with metastasis-free survival 
during 10-year follow-up, whereas HER2 status was 
not found to be significantly associated in this smaller 
sub-cohort (N = 131 of the whole TMA cohort (N 
= 218), although there were only 22 (17%) HER2 IHC 
positive case) (Figure 5B, Supplementary Table S1). 
In multivariant Cox survival model high/low FRET 
efficiency and lymph node positivity were significantly 
associated with metastasis-free survival (Table 2). 
Furthermore, since HER2-HER3 dimer formation did not 
depend on the relative concentrations of HER2 protein 
(Figure 2C), our finding that FRET efficiency is prognostic 
for determining the time to distant metastasis (Figure 5B) 
indicates a potential new prognostic biomarker.
DISCUSSION
The HER2-HER3 heterodimer is believed to be the 
most active oncogenic HER dimer, efficiently driving 
cellular proliferation via the PI3-kinase (PI3K)/AKT and 
MAPK pathways [43–45]. In this study we demonstrate 
the use of our recently improved FLIM analysis method 
[32] to derive an accurate quantification of HER2-HER3 
dimer in FFPE breast samples. We show that we can 
readily quantify HER2-HER3 dimer formation across a 
range of HER2 expression scores (i.e. 0-3+, Figure 2C). 
As predicted from the preclinical data concerning the role 
of HER2-HER3 dimer in driving cellular proliferation, 
there was a significant association of HER2-HER3 dimer 
Figure 3: HER2 and HER3 expression levels from IIlumina HT12 microarray. Data are shown for all samples with FRET 
imaging data for which HER2 status is available by TMA IHC (left: HER2-negative; right: HER2-positive). Points: red, FRET high; black, 
FRET low. The FRET efficiency threshold to define FRET high/low samples (FRET efficiency = 8.56%) was selected using an exploratory 
ROC curve analysis to identify an optimal dichotomization (see Methods).
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levels with recurrence of the disease (Table 2). Lymph 
node status was also prognostic for recurrence in this 
multivariate analysis, as expected. The HER2-HER3 
dimer measure is a promising new biomarker to predict 
the likelihood of disease progression due to metastasis up 
to 10 years from the time of diagnosis (Figure 5B).
Interestingly, the mean proportion of HER3 that 
interacts with HER2 (as measured by FRET efficiency 
[46, 47]) does not correlate with the expression of HER2 
by IHC, in contrast to that reported using PLA. At a 
theoretical level, we conducted simulations applying a 
model taking into account the complex interactions in 
a network of all 4 HER proteins [41] that demonstrated 
that a lack of correlation between HER2-HER3 dimer 
and HER2, HER3 levels could be commonly observed 
(Figure 4).  Overexpression of other members of the HER 
family potentially interferes with the observed correlation 
between, e.g. HER2 overexpression and HER2-HER3 
dimerization within the proposed mathematical model. 
This effect is likely to be more profound in biological 
Figure 4: Absence of correlation between level of HER2-HER3 dimer and total HER2, HER3 abundances is revealed 
by mathematical modelling. (A) Schematic diagram of a simple interaction model between HER1, HER2 and HER3. (B) Schematic 
diagram of HER1-4 interaction model with possible dimerization events including homo- and hetero-dimerization. The receptors are 
denoted as E1, E2, E3 and E4 for simplicity in the schemes, species Eij indicates the dimer formed between receptor Ei and Ej (the indexes 
i and j are between 1 and 4). (C, D) Lack of correlation between steady-state level of the HER2-HER3 dimer and both HER2, HER3 
abundances, simulated for 400 simulated patients in the simplified model, when [HER2 total] ~  [HER3 total]  << [HER1 total] (C) and 
[HER2 total] <<  [HER3 total]  << [HER1 total] (D). (E) Lack of correlation between steady-state level of the HER2-HER3 dimer and both 
HER2, HER3 abundances simulated for 400 simulated patients in the detailed model, when [HER2 total] ~ [HER3 total] << [HER1 total]. 
Models description is given in the Supplementary Material, Tables S1–S5.
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samples due to possible interactions between HER2 
and HER3 and proteins outside of the HER family. 
Quantification of the levels of, for instance, HER 3 
and EGFR have been associated with response to 
targeted therapies such as lapatinib [48], or resistance to 
trastuzumab [49], respectively. These data suggest that 
dimerization between alternate members of the HER 
family may be more influential in predicting response to 
HER2 targeted treatments, than levels of HER2 alone, in 
support of our mathematical model.
Despite the development of efficacious targeted 
treatments, such as the monoclonal antibody pertuzumab, 
targeted against HER2-HER3 dimerization, no gold 
standard test has yet been validated to measure the 
effects of this drug on dimer formation. PLA has been 
successfully used on FFPE samples to quantify HER2 
homodimerization and HER2-HER3 heterodimerization 
[23, 24]. However, it is difficult to compare precisely the 
distance/proximity requirement between FLIM-FRET 
and PLA. For PLA (primary plus secondary antibodies 
conjugated to oligonucleotides), the antigenic determinants 
recognized by two antibodies that are directly conjugated 
to oligonucleotides, has been estimated to be roughly 
30 nm, including the dimensions of the two antibodies 
and the connecting oligonucleotides [25]. FRET is 
rarely detected beyond 1.5 × R0, which usually amounts 
to < 10 nm between the centres of donor and acceptor 
fluorophores) [15, 16, 18, 46, 50]. Hence, FLIM-FRET 
Figure 5: Kaplan-Meier (KM) curves off distant metastasis free survival versus FRET efficiency or HER2 status 
shown for follow up periods off 5 years (left) and 10 years (right). (A) KM plots for HER positive and negative tumor samples. 
(B) KM plots for high and low FRET efficiency.
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is likely to offer a more specific quantification of protein-
protein interaction compared to PLA. Other techniques 
such as enzyme-linked immunosorbent assay (ELISA) 
and PCR-based techniques have been used to assess HER2 
overexpression [19]. However elevated levels of HER2 
extracellular domain, as measured by ELISA, were not 
reliably correlated with response to treatment or outcome 
and although PCR-based assays are sensitive and more 
quantitative, they do not preserve tissue morphology and 
samples may be contaminated by normal tissue.
Regardless of the reason for the discrepancy between 
the FLIM analysis and that based on the commercial PLA 
assay, the HER2 concentration independence could make 
the FLIM-based HER2-HER3 proximity parameter a 
useful additional marker in its utility to guide treatment 
decision/stratification among patients with HER2 
negative tumors [51], as well as those overexpressing 
HER2. Some clinical studies have shown that HER2 
overexpressing breast cancers are more likely to respond 
to lapatinib yet a small group of patients with normal or 
absent levels of HER2 can potentially also benefit from 
this treatment [52]. Other recent studies also suggest that 
some HER2 negative tumors can gain moderate benefit 
from trastuzumab treatment although robust biomarkers 
are needed for this indication (NSABP B-47) [53]. As we 
have seen, the degree of HER2-HER3 dimer formation 
can occur irrespective of the concentration of HER2. 
This heterodimer, as measured by FLIM histology, may 
therefore offer a new marker of HER2 dependency of the 
tumor (for cell proliferation, for instance) in the absence 
of HER2 overexpression (i.e. in HER2 negative patients). 
Although this study was carried out in a retrospective 
cohort with relatively small numbers of HER2 positive 
positives, further validation in a larger dataset is also 
planned.
MATERIALS AND METHODS
Antibodies
Anti-HER3 (clone B9A11, recognise intracellular 
epitop) was purchased from Monogram Biosciences Inc., 
anti-HER2 (clone e2-4001+3B5, recognise intracellular 
epitop) was purchased from ThermoScientific Ltd. and 
directly labelled according to the manufacturer’s protocol 
with Alexa546 (X546) and Cy5, respectively. 
The primary antibodies were directly labelled 
with fluorophore at particular dye/protein (D/P) ratio for 
optimal performance of the FLIM-FRET assay (donor 1:1 
and acceptor 1:3), as previously described [57]. The anti-
Table 2: Full multivariate Cox models of clinico-pathological and imaging data
Multivariate; N = 107 with complete data
5 yr DMFS 10 yr DMFS
HR (95% C.I.) P HR (95% C.l.) P
FRET efficiency
   High vs. Low (< 8.56%) 5.21 (1 84–14 78) 0.002 3.91 (1.61–9.5) 0.003
HER2 status (TMAIHC)
   Positive vs. Negative 1.12 (0.35–3.63) 0.85 0.99 (0.34–2.85) 0.99
HER3 localisation
   (C + M) vs. C 1.11 (0.39–3.16) 0.85 1.01 (0.4–2.57) 0.99
   (M/M + C) vs. C 0.54 (0.13–2.18) 0.38 0.66 (0.22–1.98) 0.45
ER status
   Positive vs. Negative 0.67 (016–2 73) 0 57 0.56 (017–1 87) 0.35
PR status
   Positive vs. Negative 1.10 (0.33–3.75) 0.87 0.73 (0.27–2) 0.54
Tumour size
   > 20 mm vs. < 20 mm 1.32 (0.46–3.83) 0.61 1.32 (0.54–3.21) 0.55
Grade
   3 vs. (1 or 2) 1.26 (0.4–3.96) 0.69 0.62 (0.24–1.62) 0.33
Lymph nodes positive
   (1–3) vs. 0 3.30 (0.99–11.01) 0.05 3.20 (1.19–8.63) 0.02
   (> 3) vs. 0 7.86 (1.73–35.57) 0.007 6.44 (1.73–23.97) 0.006
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HER3 IgG (Supplementary Figure S1B) was labelled with 
Alexa546 (X546) (donor fluorophore) at D/P ratio ~1.0 
and anti-HER2 (Supplementary Figure S1A) was labelled 
with Cy5 at D/P ratio ~3–4 (making it suitable as an 
acceptor in the assay), while retaining antigen specificity 
in FFPE samples.
Plasmids
The HER3-HA construct was made by excision of 
HER3 from HER3-GFP (a kind gift from Selene Roberts, 
Rutherford Appleton Laboratory (RAL)) with NheI and 
KpnI, and ligation into pCDNA3.1 (Invitrogen) containing 
an HA tag. The construct was used for validation of anti-
HER3-IgG specificity in FFPE samples (Supplementary 
Figure S1B). 
Cell culture and plasmid transfection
SKBR3 cells (a gift from the Breakthrough Breast 
Cancer Unit, Guys Hospital) and MCF-7 cells were 
cultured in DMEM supplemented with 10% FCS. Cells 
were validated by STR genotyping in ICR, UK. Cells 
were transfected with plasmid DNA (HER3-HA) using 
FuGene6 (Promega) according to the manufacturer’s 
protocol, and cultured for 24 hours. Cells were fixed with 
10% formalin for 5 hours and paraffin wax processed 
following a standard procedure.
Patient samples and protein detection
Tissue microarrays (TMA) were created from 218 
primary breast cancers from patients included in the 
METABRIC (Molecular Taxonomy of Breast Cancer 
International Consortium) study [58], from the King’s 
Health Partners Cancer Biobank. Distant metastasis-
free survival was defined as the time period from date of 
diagnosis to first distant relapse or disease-specific death. 
The immunohistochemical (IHC) detection of HER2 
used the HercepTest™, (Dako, Glostrup, Denmark) 
and antigen retrieval for immunofluorescence (IF) with 
directly labelled antibodies was performed using the 
Ventana BenchMark ULTRA system, in accordance with 
the manufacturer’s instructions.
TMA sections were cut and either stained with 
anti-HER3 alone (donor only) or anti-HER3 and anti-
HER2 antibodies simultaneously (donor with acceptor). 
Expression of HER3 was assessed using the epifluorescence 
images from the donor only slides, prior to FLIM-FRET 
imaging. As there is no validated method for scoring HER3 
expression, and levels vary greatly at the membrane and 
intra-cellularly, the presence of the receptor was scored 
according to the descriptive key:
M/M+C = membrane staining only or predominantly 
membrane, some cytoplasmic present (this combination of 
membrane only and membranous and cytoplasmic staining 
was selected due to the small numbers of cores which 
were scored as showing membrane staining only (n = 6));
C = cytoplasmic staining only
C + M = predominantly cytoplasmic staining, some 
occasional membrane
NA = Not Assessable
Sections were stored at −20°C until imaged. 
Imaging and image analysis
Samples were imaged on an customised “open” 
microscope automated FLIM system [59]. Time-
domain fluorescence lifetime images were acquired 
via time correlated single photon counting (TCSPC) at 
a resolution of 256 by 256 pixels, with 256 time bins 
and 100 frames accumulated over 300 seconds, via 
excitation and emission filters suitable for the detection 
of Alexa546 fluorescence (Excitation filter: Semrock 
FF01-540/15-25; Beam Splitter: Edmund 48NT-392 
30R/70T; Emission filter: Semrock FF01-593/40-25). 
For technical convenience, those FLIM images were 
acquired through the emission channel of a UV filter 
cube (Long pass emission filter > 420 nm). Conventional 
wide field fluorescence images were acquired with filter 
cubes for Alexa546 (Excitation 530–560 nm, emission 
573–648 nm) and Cy5 (Excitation 590–650 nm, emission 
663–738 nm), at a resolution of 1024 by 1024 pixels on 
a CCD camera (Hamamatsu 1394 ORCA-ERA), with an 
exposure time of typically 100–500 ms. For each sample 
a ‘donor’ image and a ‘donor with acceptor’ image were 
acquired from serial sections, of the same area of the 
tissue core.
FLIM analysis was performed with the TRI2 
software (Version 2.7.8.9, Gray Institute, Oxford) as 
described previously [60, 61]. Interfering effects of 
autofluorescence were minimised using processing with 
lifetime filtering algorithm [32]. The FRET efficiency 
for each tissue sample region of interest was calculated 
according to the equation FRET eff = 1–(τDA/τD), where 
τD is the average lifetime of Alexa546 in the absence of 
Cy5 from the donor image and τDA is the average lifetime 
of Alexa546 in the presence of Cy5, from the ‘donor with 
acceptor’ image.  
mRNA expression
Illumina HumanHT-12 v3 Expression BeadChip 
data for METABRIC samples [58] were previously 
deposited in the European Genome-Phenome Archive 
(accession number EGAD00010000162). Raw probe-level 
data for all METABRIC samples from the King’s BioBank 
were filtered to remove arrays with outlying low intensity 
(mean log2 expression < 5.6), quantile normalised using 
the ‘beadchip’ package for R/Bioconductor, filtered for 
probe detection (p < 0.01 on more than 1% of samples) 
and COMBAT corrected for beadchips.
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Statistical analysis
Kaplan-Meier curves and Cox proportional 
hazards models were fitted using R ‘survival’ package 
[62]. Univariate and full multivariate Cox models were 
fitted to the data. Receiver operating curves (ROC) were 
plotted using the ‘pROC’ package [63], using FRET as 
a discriminator of metastasis-free survival. From these 
ROC curves an optimal FRET threshold was chosen by 
the “Youden” method with equal weights for sensitivity 
and specificity, separating the patients into FRET ‘high’ 
and ‘low’ groups. 
CONCLUSIONS
Currently, detection of HER2 protein expression 
or gene amplification is central to the management of 
breast cancer patients and is carried out according to 
standardized guidelines [4]. However, the heterogeneity 
of HER2 expression [54], along with its ability to form 
heterodimers with other members of the HER family 
[1, 55], create a significant degree of uncertainty 
in reliably predicting response to treatment [54]. 
In support of the preclinical data pertaining to the 
importance of the HER2-HER3 heterodimer, clinical 
blockade of HER2 heterodimer formation by the 
addition of the novel drug, pertuzumab, to trastuzumab, 
has been shown to significantly improve the 
progression-free survival  in patients with metastatic 
HER2+ breast cancer [56]. However, no novel 
biomarkers have been validated to predict response 
to treatment. We have demonstrated the feasibility 
of quantification of the HER2-HER3 heterodimer in 
FFPE breast tissue samples. Our assay is prognostic 
for metastatic recurrence up to 10 years, independent 
of routine clinico-pathological biomarkers, including 
HER2 overexpression. The assay could, if validated in a 
group of patients treated with, for instance pertuzumab, 
be used as a predictive biomarker to predict for 
response to such targeted therapies, in order to increase 
the therapeutic efficiency within the subgroup chosen 
and therefore also further increase the survival benefit 
obtained by adding pertuzumab to the trastuzumab-
chemotherapy regime. The evolution of future anti-
cancer treatments including the anti-HER3 agents under 
investigation might be enhanced by a robust, validated 
marker  of HER2-HER3 dimerisation; in analogy to 
the potential role of EGFR-HER3 dimer in conferring 
resistance to cetuximab/panitumumab in the case of 
basal-like breast cancer patients [14]. By choosing 
the patient most likely to require and achieve a good 
response to anti-HER2 therapy, we can truly apply 
drugs where they are needed. By refining treatment via 
biomarker driven selection of drugs we can reduce the 
burden of toxicity and improve efficacy and efficiency 
without invariably increasing healthcare costs.
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